These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33300337)

  • 1. Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case.
    Spitaleri A; Zia SR; Di Micco P; Al-Lazikani B; Soler MA; Rocchia W
    J Phys Chem Lett; 2021 Jan; 12(1):49-58. PubMed ID: 33300337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.
    Lin YL; Meng Y; Huang L; Roux B
    J Am Chem Soc; 2014 Oct; 136(42):14753-62. PubMed ID: 25243930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico Reoptimization of Binding Affinity and Drug-Resistance Circumvention Ability in Kinase Inhibitors: A Case Study with RL-45 and Src Kinase.
    Koneru JK; Sinha S; Mondal J
    J Phys Chem B; 2019 Aug; 123(31):6664-6672. PubMed ID: 31310546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does a drug molecule find its target binding site?
    Shan Y; Kim ET; Eastwood MP; Dror RO; Seeliger MA; Shaw DE
    J Am Chem Soc; 2011 Jun; 133(24):9181-3. PubMed ID: 21545110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Src Inhibitors: Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
    Zhang Y; Zhang TJ; Tu S; Zhang ZH; Meng FH
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32911607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced efficacy of a Src kinase inhibitor in crowded protein solution.
    Kasahara K; Re S; Nawrocki G; Oshima H; Mishima-Tsumagari C; Miyata-Yabuki Y; Kukimoto-Niino M; Yu I; Shirouzu M; Feig M; Sugita Y
    Nat Commun; 2021 Jul; 12(1):4099. PubMed ID: 34215742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations.
    Mingione VR; Foda ZH; Paung Y; Philipose H; Rangwala AM; Shan Y; Seeliger MA
    J Mol Biol; 2022 Sep; 434(17):167628. PubMed ID: 35595169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
    Johnson TK; Soellner MB
    Bioconjug Chem; 2016 Jul; 27(7):1745-9. PubMed ID: 27266260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for selective inhibition of Src family kinases by PP1.
    Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM
    Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
    Zhou P; Hou S; Bai Z; Li Z; Wang H; Chen Z; Meng Y
    Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1122-1131. PubMed ID: 28754059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, Biological, and Computational Evaluation of Novel 1,3,5-Substituted Indolin-2-one Derivatives as Inhibitors of Src Tyrosine Kinase.
    Kilic-Kurt Z; Bakar F; Ölgen S
    Arch Pharm (Weinheim); 2015 Oct; 348(10):715-29. PubMed ID: 26260414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture.
    Fang L; Vilas-Boas J; Chakraborty S; Potter ZE; Register AC; Seeliger MA; Maly DJ
    ACS Chem Biol; 2020 Jul; 15(7):2005-2016. PubMed ID: 32479050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
    Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
    J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
    Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
    Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II.
    Maeda M; Shintani Y; Wheelock MJ; Johnson KR
    J Biol Chem; 2006 Jan; 281(1):59-68. PubMed ID: 16267045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation pathway of Src kinase reveals intermediate states as targets for drug design.
    Shukla D; Meng Y; Roux B; Pande VS
    Nat Commun; 2014 Mar; 5():3397. PubMed ID: 24584478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
    Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
    Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate binding to Src: A new perspective on tyrosine kinase substrate recognition from NMR and molecular dynamics.
    Joshi MK; Burton RA; Wu H; Lipchik AM; Craddock BP; Mo H; Parker LL; Miller WT; Post CB
    Protein Sci; 2020 Feb; 29(2):350-359. PubMed ID: 31697410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
    Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
    ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystallography for protein kinase drug design: PKA and SRC case studies.
    Breitenlechner CB; Bossemeyer D; Engh RA
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):38-49. PubMed ID: 16269279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.